← All trials
NCT03882034
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 5, 2019
- Primary completion
- Jan 1, 2022
- Completion date
- Jan 22, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institutes of Health (NIH)Lead sponsor
- National Institutes of Health (NIH)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.